3rd Quarter - Report
THE OB-C GROUP, LLC for ELI LILLY
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
HR 5629, Pathway for Biosimilars Act: biologics. S 1695, Biologics Price Competition and Innovation Act of 2007: biologics. HR 1367, Paul Wellstone Mental Health and Addiction Equity Act of 2007: mental health parity. HR 1424, Emergency Economic Stabilization Act of 2008: mental health parity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL S JOHNSON | — |
| THOMAS J KEATING | — |
| ROBERT H MARSH | — |
| CHARLES J MELLODY | — |
| NATHAN J MILLER | — |
| PATRICIA A NELSON | — |
| LAWRENCE F O'BRIEN, III | — |
| ROBERT G STEVENSON | — |
Copyright/Patent/Trademark CPT
S 1145, Patent Reform Act of 2007: patent reform. HR 1908, Patent Reform Act of 2007: patent reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL S JOHNSON | — |
| THOMAS J KEATING | — |
| ROBERT H MARSH | — |
| CHARLES J MELLODY | — |
| NATHAN J MILLER | — |
| PATRICIA A NELSON | — |
| LAWRENCE F O'BRIEN, III | — |
| ROBERT G STEVENSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.